Fondation partenariale FMC VIA-LR, MACVIA-France, Montpellier, France.
INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France.
Allergy. 2019 Dec;74(12):2329-2341. doi: 10.1111/all.14068.
The European Academy of Allergy and Clinical Immunology (EAACI) supports three journals: Allergy, Pediatric Allergy and Immunology, and Clinical and Translational Allergy. EAACI's major goals include supporting the promotion of health, in which the prevention of allergy and asthma plays a critical role, and disseminating the knowledge of allergic disease to all stakeholders. In 2018, the remarkable progress in the identification of basic mechanisms of allergic and respiratory diseases as well as the translation of these findings into clinical practice were observed. Last year's highlights include publication of EAACI guidelines for allergen immunotherapy, many EAACI Position Papers covering important aspects for the specialty, better understanding of molecular and cellular mechanisms, identification of biomarkers for disease prediction and progress monitoring, novel prevention and intervention studies, elucidation of mechanisms of multimorbidities, introduction of new drugs to the clinics, recently completed phase three clinical studies, and publication of a large number of allergen immunotherapy studies and meta-analyses.
欧洲过敏与临床免疫学会(EAACI)支持三种期刊:《过敏》《儿科过敏与免疫学》和《临床与转化过敏》。EAACI 的主要目标包括支持促进健康,其中预防过敏和哮喘起着关键作用,并向所有利益相关者传播过敏疾病的知识。2018 年,观察到在鉴定过敏和呼吸道疾病的基本机制方面取得了显著进展,以及将这些发现转化为临床实践。去年的亮点包括发布 EAACI 过敏原免疫疗法指南、涵盖专业重要方面的许多 EAACI 立场文件、对分子和细胞机制的更好理解、鉴定用于疾病预测和进展监测的生物标志物、新的预防和干预研究、阐明多种疾病的机制、将新药引入临床、最近完成的三期临床研究,以及发表了大量过敏原免疫治疗研究和荟萃分析。